MARATTO

article · Journal of Medicinal Chemistry

Examination of Coligands in Mefloquine–Metal Complexes Reveals the Structural Determinants of Activity against <i>Plasmodium falciparum</i> and <i>Schistosoma mansoni</i>

Abstract

Mefloquine (MQ) is an important component for antiparasitic therapy. Herein, the synthesis and antiplasmodial and antischistosomal activities of MQ-metal complexes of the general formula [M(II)(L)(MQ)]PF<sub>6</sub> are described. Variation of the metal center (platinum and palladium) and coligand (phosphine or bipyridine) consistently yielded MQ coordinated as a <i>N</i>,<i>O</i>-bidentate ligand. Biological evaluation against <i>Plasmodium falciparum</i> and <i>Schistosoma mansoni</i> revealed that the metal center augmented the antiparasitic property of MQ by functioning as a thioredoxin/glutathione reductase-targeting moiety, while the coligand modulated chemical reactivity and physicochemical properties. MQ-Pt complexes displayed high <i>in vivo</i> efficacy. The intracellular accumulation of the metal in parasite cells contributed to the abrogation of essential biochemical pathways. Notably, despite being isostructural, Pd complexes differed from their Pt counterparts in their ligand dissociation behavior. The current work establishes a new structural framework for developing metal-based antiparasitic agents capable of selectively targeting essential parasite biochemical pathways while sparing mammalian cells.

Research topics

  • Metal complexes synthesis and properties
  • Malaria Research and Control
  • Parasites and Host Interactions

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1021/acs.jmedchem.5c03739

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.